FDA wants suffixes to distinguish biosimilars from biologics

01-09-2015

FDA wants suffixes to distinguish biosimilars from biologics

STILLFX / Shutterstock.com

The US Food and Drug Administration (FDA) has proposed using four-letter suffixes to name biosimilar drugs.


Biosimilar, US Food and Drug Administration, FDA, nonproprietary name, Sandoz, Zarxio, Amgen, Neupogen

LSIPR